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Abstract
Introduction Biomarker discovery is a major objective of
clinical proteomics; molecular biomarkers allow for detec-
tion of early-stage human diseases, especially cancer, and
for monitoring their progression and/or regression after
treatment. Biomarkers also help to elucidate the pathology
of disease and its diagnosis, drug discovery, and toxicology.
Glycans are ideal candidates for biomarkers because (1)
glycoconjugates are localized on the cell surface and in the
secretions such as plasma, (2) their structures are frequently
and drastically changed during normal and aberrant cell
differentiation, and (3) different cell types express different
glycan signatures. Certain serodiagnostic glycoconjugate
markers, such as carcinoembryonic antigen (CEA), are
currently available; however, comprehensive glycome
analysis has yet to be performed, mainly because of the
difficulties of isolating and structurally analyzing complex
glycans. Large-scale glycoprotein analysis, termed glyco-
proteomics, has the potential to effectively trace cellular
glycoproteins and therefore to search for new serodiagnostic
biomarkers.
Conclusions In this review, we describe current mass
spectrometry-based glycoproteomics technologies. Quantita-
tive “shotgun” proteomics analyses of glycopeptides captured
from complex biological mixtures such as plasma, coupled
with advanced glycome technologies, enhance our knowledge
of protein glycosylation and facilitate discovery of new
biomarkers for human diseases.
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Introduction
Recent advances in proteomics and related computational
science, combined with advanced cell biology technologies,
are uncovering molecular mechanisms for various biological
processes. In clinical science, much attention is focused on
understanding the pathophysiology of human disease,
especially neoplastic cell transformation, to develop new
therapeutic targets and to discover biomarkers that correlate
with early diagnosis, drug development, and toxicology. The
US Food and Drug Administration has approved 20
molecular biomarkers for clinical use to detect and monitor
human diseases, including cancer (1). Most of these markers
were identified by hybridoma screening, where the anti-
bodies were generated by immunization with target cells,
followed by antigen identification (2); however, proteomics
is an alternative approach for biomarker discovery that
would permit quantitative analysis of protein changes
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associated with disease development, such as tumor
growth, in a “genome-wide” scale.
Numerous studies have aimed to discover new cancer
biomarkers, mostly through differential protein analysis
between normal and cancerous tissue samples. For instance,
two-dimensional gel electrophoresis analyses of various
tumor samples taken during surgery or captured by laser
microdissection have provided candidate cancer biomarkers
(3–5). Likewise, proteomic analyses of bodily fluids, such as
plasma and urine, have been used to identify tissue-specific
diagnostic biomarkers for early-stage cancer (1, 6–8). Human
plasma has been the primary focus because its components
originate from a variety of tissues/cells. However, the
difficulty in analyzing the plasma proteome is widely
recognized—Notably, there is enormous dynamic range with
regard to the highest and lowest concentration of compo-
nents, and a single component, albumin, accounts for
approximately half of the total protein mass in plasma
(55mg ml−1); moreover, roughly ten major proteins comprise
90% of the total protein mass. In contrast, the trace plasma
components such as the cytokine interleukin-6 are present at
1–5pg ml−1; the difference in concentration between albumin
and interleukin-6 is thus 1010 (9). Because this dynamic
range appears far beyond the analytical range (103–104) of
current proteomic technology, it is clear that new and highly
sensitive proteomic methods for enrichment of trace bio-
marker candidates are key for searching for new diagnostic
biomarkers in plasma.
Glycoproteins are potential diagnostic biomarkers because
most secretory proteins are glycosylated, and their glycan
structures frequently and drastically change during tumori-
genesis as well as in normal cell differentiation. Glycans are
the first cellular components encountered by approaching
cells, pathogens, antibodies, or other molecules. In addition,
they are often used as specific cell biomarkers at different
stages of differentiation. Different cell types express different
glycan signatures. These two fundamental characteristics of
glycoproteins, i.e., common posttranslational modification in
secretory proteins and lineage-specific signatures of glycans,
make them ideal candidates for cancer biomarkers. Most
cancer-related biomarkers available to date, such as CA19.9,
prostate-specific antigen, CEA, and α-fetoprotein, are glyco-
proteins or glycoconjugates (1). In this review, we summarize
mass spectrometry (MS)-based glycoproteomic technologies
for cancer biomarker discovery, with a special focus on pre-
proteomic analysis enrichment of glycopeptides from com-
plex biological mixtures and their assignments and structural
analysis by MS.
Enrichment of Glycopeptides for MS-Based Proteomics
Although there are reports of glycoproteome analyses based
on electrophoresis techniques (10–12), the MS-based
“shotgun” approach has advantages in speed, sensitivity,
and automation. It is particularly suitable for glycoproteomics
analysis because this method allows for the identification of
glycoproteins regardless of their subcellular localization
(many glycoproteins are integrated into membranes) or
structure (most glycoproteins are heterogeneous in charge
and molecular size and thereby give rise to multiple or smear
spots in two-dimensional polyacrylamide gel electrophoresis).
Thus, most of the large-scale glycoproteome analyses have
used the shotgun approach; however, the key goal is to capture
minor glycopeptides efficiently from samples containing large
numbers of non-glycosylated peptides produced by proteo-
lytic digestion of complex protein mixtures such as crude
cellular extracts, tissues, or plasma.
Affinity Chromatography for Capturing Glycopeptides
Lectins More than 2,000 lectins have been detected from
various sources (13–15), and about 200 of those are
characterized in amino acid sequence, hemagglutinating
activity, tertiary structure, etc. (http://proline.physics.iisc.
ernet.in/cgi-bin/cancerdb/input.cgi/; and http://nscdb.bic.
physics.iisc.ernet.in/). Although the binding specificities
and kinetic parameters remain largely unknown, they are
useful tools to capture, concentrate, and classify glycocon-
jugates, including glycoproteins and glycopeptides (Fig. 1).
Because non-reducing ends of naturally occurring glycans
are limited to mannose, galactose, N-acetylglucosamine,
sialic acids, and rarely N-acetylgalactosamine, a number of
lectins with binding specificities to these glycans can be
used to capture subsets of the glycoproteome (Table 1). For
a more comprehensive or systematic collection of glyco-
peptides from complex biological mixtures, multiple lectins
with distinct binding specificities are used in combination
or in series (16–20). For instance, we applied three lectin
columns bound with concanavalin A (ConA), wheat germ
agglutinin (WGA), or worm galectin 6 for a comprehensive
analysis of N-linked glycoproteins in Caenorhabditis
elegans and identified 1,465 N-glycosylated sites on 829
unique proteins, including 224 putative secretory and 432
membrane-bound N-glycoproteins with single or multiple
transmembrane segments (21). Interestingly, the glycosyla-
tion site was used as a landmark for analysis of the topology
of membrane-bound N-glycoproteins because the initial
protein glycosylation takes place only in the endoplasmic
reticulum lumen and the glycosylated segments do not cross
the membrane bilayer. Based on a topological analysis of
257 N-glycosylated proteins containing putative single
transmembrane segments, we suggested an atypical non-
cotranslational translocation mechanism for integral mem-
brane proteins (21). We also note that many N-glycoproteins
identified in this study have mammalian counterparts that are
classified as disease-related genes/proteins (data not shown).
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Yang et al. (22) performed a comparative glycoproteome
analysis of sera from breast cancer patients and normal
controls using a mixed-bed column of Jacalin-, ConA-, and
WGA-agarose. The authors identified 813 glycoproteins in the
serum samples, including low-abundance components such as
neuropilin-1 and pregnancy zone protein, and found a
difference in the expression of a number of proteins associated
with lipid transport and cell growth. Likewise, Drake et al. (23)
analyzed human plasma glycoproteins captured by various
lectins and found a difference between sera from subjects
with benign prostatic hyperplasia and prostate cancer or
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Fig. 1 Methods to capture glycopeptides. (1) Lectin/antibody-
mediated affinity chromatography, (2) hydrazide chemistry-based
covalent capturing, (3) BEMAD and subsequent disulfide formation,
(4, 5) metabolic incorporation of azidosugar and ligation of biotin/
FLAG tags via (4) Staudinger ligation or (5) Huisgen cycloaddition,
and (6) enzymatic addition of a keto-derivative of Gal onto O-GlcNAc
and subsequent incorporation of biotin tag. Black hexagon sugar
chain, gray hexagon Gal, white hexagon O-GlcNAc
Table 1 Lectins used for glycopeptide capture and their binding specificity for glycans
Lectin Source Specificity
ConA Canavalia ensiformis α-Man (no binding in the presence of bisecting GlcNAc)
GNA Galanthus nivalis Non-substituted a1–6Man
MAL Maackia amurensis Siaα 2–3Galβ1–4Glc(NAc)
SSA Sambucus sieboldiana Siaα 2–6 Galβ1–4Glc(NAc)
MAH Maackia amurensis Siaα2–3Gal
WGA Triticum unlgari Multivalent Sia and (GlcNAc)n
LTL Lotus tetragonolobus Fucα1–3GlcNAc, Sia-Lex, and Lex
PHA-E Phaseolus vulgaris Bisecting GlcNAc and biantennary N-glycans
GSL-II Griffonia simplicifolia GlcNAc and agalactosylated N-glycans
LCA Lens culinaris Fucα1–6GlcNAc (core fucose)
UEA-I Ulex europaeus Fucα1–2 Galβ1–4Glc(NAc)
AOL Aspergillus oryzae Fucose
AAL Aleuria aurantia Fucose
LEL Lycopersicon esculentum Poly-LacNAc and (GlcNAc)n
DSA Datura stramonium Poly-LacNAc and branched LacNAc
ECA Erythrina cristagalli Galβ1–4Glc(NAc)
RCA120 Ricinus communis Galβ1–4Glc(NAc)
Jacalin Artocarpus integrifolia Galβ1–3GalNAcα-Ser/Thr (T) and GalNAcα-Ser/Thr (Tn)
PNA Arachis hypogaea Galβ1–3GalNAcα-Ser/Thr (T)
WFA Wisteria floribunda Terminal GalNAc (e.g., GalNAcβ1–4GlcNAc)
Man mannose, GlcNAc N-acetylglucosamine, Sia sialic acids,Gal galactose, Fuc fucose, LacNAc Galβ1–4GlcNAc, GalNAc N-acetylgalactosamine,
T T antigen, Tn Tn antigen
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control subjects. Thus, MS-based analysis of lectin-captured
glycopeptides allows for large-scale glycoproteome analysis
and identifies cancer biomarker candidates.
To assist lectin-based analyses of glycoproteins, an
automated high-throughput method, based on frontal
affinity chromatography (24), was recently developed (25)
and applied to the comprehensive interaction analysis
between ∼100 lectins and ∼100 glycans (the data for 50
typical lectins will become available soon at the Japan
Consortium for Glycobiology and Glycotechnology Data-
base, http://www.jcgg.jp/E/index.html). Though certain
lectins have a broad binding specificity to glycans and the
binding capacities of lectins are affected by the tertiary
structure of glycoconjugates (26), a large-scale dataset of
the lectin/glycan interactions will help to select lectins for
glycoproteome analysis.
Antibodies Against Glycans Antibodies against glycans
have been used to capture glycoproteins having a static
glycan structure (27–29). Lewis X is a prominent member
of the Lewis blood group antigen family that can be found
on glycoproteins, glycolipids, and proteoglycans. Its anti-
genicity is noted by the fact that many research groups have
generated monoclonal antibodies against this trisaccharide
structure while studying developmental processes or cancer.
This type of antibody is applicable for glycoproteomics
analysis; however, the application of antibody-mediated
glycopeptide capture is limited because the glycans,
especially N-glycans, are generally poor antigens because
of their structural conservation among immunized animal
species.
Glycoprotein Receptors Glycoprotein receptors are alterna-
tive tools to collect specific glycoprotein subsets. For instance,
Sleat et al. used mannose-6-phosphate (M6P) receptors to
capture N-glycoproteins and identified many known, as well
as unknown, M6P-motifs containing glycoproteins in human
brain lysosomes (30), plasma (31), and urine (32) samples.
The authors suggested that the method might be able to
search for biomarkers of lysosomal disorders.
Chemical Coupling to Capture Glycopeptides
The method developed by Zhang et al. (33) captures
glycopeptides on a solid support by chemical coupling
between cis-diol groups of the glycan and hydrazide on the
support. N-linked glycopeptides are then released from the
resin by digestion with peptide: N-glycanase (PNGase;
Fig. 1). Unlike lectin affinity chromatography, the method
captures N-linked glycopeptides regardless of the glycan
structure. Modification of this original protocol includes
incorporation of a stable isotope tag into peptides attached
on the solid support via the succinimidation of amino
groups for quantitative analysis (33) or introduction of
superparamagnetic silica particles with a hydrazide group to
facilitate high-throughput analysis (34). The method was
applied to various biological samples including human
plasma (35, 36), plasma of healthy and trauma patients
(37), platelets (38), saliva (39), prostate cancer epithelial
cells (33), and a microsomal fraction of cisplatin-resistant
ovarian cancer cells (40).
On the other hand, a unique technology based on β-
elimination followed by Michael addition with dithiothreitol
(DTT), termed BEMAD, captures O-linked glycopeptides
(41) (Fig. 1). The introduced thiol group is attached to a
thiol-containing solid support, such as thiol-Sepharose,
through a disulfide bond. After removing non-O-glycosylated
peptides by washing the support with appropriate buffer, the
captured formerly O-glycosylated peptides are recovered by
elution with DTT. Because the β-elimination reaction also
occurs at O-phosphorylated or O-sulfated Ser/Thr residues
in the sample mixture, the method should be coupled with
an enrichment of O-glycosylated peptides by, for instance,
lectin affinity chromatography on a WGA column. By
using this method in combination with MS3- and electron-
transfer dissociation (ETD)-MS techniques, Vosseller et al.
(42) identified 65 O-glycosylated peptides in 18 proteins
from mouse brain postsynaptic density preparations and
predicted the substrate specificity of mammalian O-GlcNAc
transferase.
Carbohydrate-Tags via Metabolic or Chemo-enzymatic
Labeling
Two methods have recently been developed to introduce
a specific affinity tag to capture glycoproteins and
glycopeptides from complex mixtures (Fig. 1). One
method, called the “tagging-via-substrate” approach, uti-
lizes peracetylated azidomonosaccharides or thiol deriva-
tives for metabolic incorporation of the artificial sugar
moiety into glycans synthesized in cultured cells or in
animals such as mice (43–50). For instance, administration
of N-α-azidoacetylmannosamine into culture media results
in incorporation of its metabolite, N-α-azidoacetyl sialic
acid, into glycoconjugates, including N-glycoproteins. The
azide group is then reacted with phosphine compounds
with a biotin or FLAG peptide tag through the Staudinger
ligation reaction (43) or with alkyne compounds with
similar tags through Huisgen [3+2] cycloaddition to label
glycoconjugates (45). The tagged glycoproteins are affinity-
captured with avidin or an antibody against FLAG. These
new techniques have identified many O-glycosylated pro-
teins in mammalian cells (43, 47, 48). However, the method
needs improvement to identify N-glycoproteins because of
the metabolic intolerance of the artificial sugar moiety to
incorporate the azide group into N-glycans.
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Another method, the “chemo-enzymatic” approach de-
veloped by Khidekel et al. (51, 52) utilizes a genetically
engineered galactosyltransferase to incorporate ketone
analogs of galactose to cellular O-glycosylated proteins,
followed by incorporation of a biotin label through
coupling with aminoxy-biotin. The method identified 25
O-glycosylated proteins in rat brain.
LC-Based Enrichment of Glycopeptides
Hydrophilic Interaction LC Because of the hydrophilic
nature of glycopeptides, hydrophilic interaction liquid chro-
matography (HILIC) on dextran/cellulose-based supports,
such as Sepharose (53, 54), or zwitterionic resin (55) has
been used to enrich glycopeptides and glycans. In HILIC,
peptide mixtures were dissolved in a hydrophobic solvent,
such as a mixture of 1-butanol, ethanol, and water (4:1:1, v/v),
applied to the column, and adsorbed glycopeptides eluted by
decreasing the concentration of 1-butanol in aqueous ethanol.
We coupled concurrent multiple lectin affinity chromatogra-
phy with HILIC and significantly improved the purity of N-
linked glycopeptides prepared from crude extracts of C.
elegans (21) or mouse tissues (Kaji et al., unpublished).
Size Exclusion Chromatography Among the in silico
tryptic peptides of human proteins listed in the National
Center for Biotechnology Information database, more than
90% are estimated to have masses smaller than 2,000Da
(56). On the other hand, masses of N-glycans are larger
than 1,200Da; thus, most N-glycopeptides able to be
identified by MS/MS as deglycosylated forms could be
enriched by size-exclusion chromatography, as demonstrated
by Alverez-Manilla et al. (56).
Boronic Acid Boronic acid forms boronic diesters through
reaction of geminal diols. Using this reactivity, boronic
acids have long been used for glycoprotein enrichment.
This method has recently been used to detect low-
abundance glycoproteins in human blood samples (57).
Strong Cation Exchanger Glycopeptides with a terminal sialic
acid can be enriched by liquid chromatography (LC) on a strong
cation exchanger column. By this method, Lewandrowski et al.
(58) identified 148 glycosylation sites on 79 sialylated
glycoproteins in a membrane fraction of human platelet.
Titanium Dioxide It has been shown that TiO2 column,
developed originally to capture phosphopeptides, was also
effective to enrich sialylated glycopeptides, probably
because sialic acid forms relatively stable bidentate bridge
with TiO2 ligand (59). The method was applied success-
fully to identify ∼100 sialo-glycoproteins in human plasma
or saliva, respectively.
Identification and Structural Analysis of Glycopeptides
Assignment of Glycopeptides
Peptide assignment in the shotgun analysis depends on
tandem MS (MS/MS) analysis of the fragment ions
generated by collision-induced dissociation (CID). Direct
CID-MS/MS analysis of glycopeptides, however, generates
preferentially a series of fragment ions derived from the
dissociation of glycosyl bonds rather than peptide bonds,
and thus, the glycan moiety needs to be removed before MS
analysis for efficient peptide assignment. Deglycosylation
has additional advantages: (1) The process increases the
analysis sensitivity because it yields non-glycosylated
peptides by removing multiple glycan forms having
different chemical characteristics, and (2) the process
allows the exploitation of stable isotope labeling of
glycosylated sites on peptides to improve the fidelity of
glycopeptide identification (60, 61). The stable isotope
label not only indicates the formerly glycosylated site but
also acts as a mass-tag for quantitative analysis (61).
Enzymatic or chemical processes are available for
the deglycosylation reaction for large-scale analysis of
glycopeptides (Fig. 2). PNGase releases N-linked glycans
of glycopeptides, regardless of the glycan structure. The
isozyme, PNGase F, is most widely used (61–63);
however, PNGase A more effectively removes the N-
linked glycans with core α(1,3)-fucose, which are found
in N-glycoproteins synthesized in plants, insects, C.
elegans, etc. Endo-α-N-acetylglucosaminidases (Endo
D/H. EC3.2.1.96.) remove N-linked glycans from glyco-
peptides, leaving a single GlcNAc residue attached to the
Asn (Fig. 2). In cases where proximal GlcNAc residues in
the chitobiose core are modified with Fuc, the core-
fucosylated proteins are identified by Endo D/H digestion
after previous digestion of the glycopeptides with siali-
dase, β-galactosidase, and N-acetyl-α-glucosaminidase
(55, 64).
O-glycans can be removed from O-linked glycopeptides
through the alkaline β-elimination reaction. After β-
elimination, several tags can be introduced at the glycosy-
lated site by reacting the dehydro-intermediate with various
thiol or amino compounds. Because the efficiency of the
reaction depends largely on the structure of glycopeptides,
the BEMAD reaction has been used for most O-GlcNAc
site mapping (41, 42).
Direct Structural Analysis of Glycopeptides
Direct MS determination of glycan structure is extremely
important for biomarker discovery, as the glycan structure
attached to a particular glycoprotein is frequently and
drastically changed during cell differentiation or tumori-
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genesis. High-speed multi-stage MS/MS technology, or
MSn, has emerged as a technology that enables both peptide
assignment and structural determination of posttranslational
modifications, such as the site of glycosylation and the
attached glycan structure (65–70). The method determines
the structure by collecting information from a series of
fragment ions generated by multiple CID processes, typically
three times (MS3; Fig. 3). It has successfully determined the
three glycosylated sites and the glycoform structures in
Thy-1, a glycosylphosphatidylinositol-anchorred protein
(67), and determined the structures of neutral and sialylated
N-glycans attached to chicken egg yolk glycopeptides (69).
Thus, the MSn technology will be a powerful tool for
glycoproteome analysis after the collection speed of MSn
spectra is increased to the LC-MS time scale.
Another approach to identify the core peptide of a
glycopeptide is via electron-capture dissociation (ECD)/
ETD technologies. ECD/ETD causes peptide bond cleavage
without cleavage of labile bonds between the peptide and
conjugated groups such as glycans and phosphates or
within glycans (71–76). Although the application of this
method has been limited to model glycopeptides, ECD/
ETD coupled with CID has the potential for complete
chemical structural determination of glycopeptides in
complex biological mixtures.
Quantitative Glycoproteomics
Differential Analysis Most technologies for quantitative
proteomics are based on differential stable-isotope labeling,
such as in vivo metabolic labeling of cultivated cells (77)
and in vitro chemical labeling using ICAT (78), MCAT
(79), iTRAQ (80, 81), and 13C, 15N-double labeled MCAT
reagents (82). These can be used in combination with
various technologies to capture glycopeptides. For instance,
Zhang et al. (33, 83) estimated a quantitative difference in
several mouse plasma glycoproteins before and after
tumorigenesis by chemical capture of N-glycopeptides and
stable isotope labeling (d0/d4) of the N-terminal amino
group with succinimidation. Ueda et al. (84) identified 34
human plasma glycoproteins with different levels of α-1, 6-
fucosylation between lung cancer patients and healthy
controls by stable isotope labeling of Trp residues with 2-
nitrobenzensulfenylation. On the other hand, two methods
allow incorporation of mass tag specifically to glycopep-
tides; one is BEMAD using deuterium-labeled DTT (42),
and the other is PNGase-mediated incorporation of 18O
specifically into Asn residues at N-glycosylated sites (61).
We confirmed the feasibility of the latter approach and
applied it to large-scale mouse glycoproteome analyses

























































   
   






GlcNAcase, Endo D/H amino acid sequence
glycosylated site
Fig. 2 Identification of glycopeptides after deglycosylation. (1)
Deglycosylation of N-glycan by PNGase and concomitant conversion
of Asn to Asp that allows a glycosylation site-specific incorporation of
18O. (2) BEMAD. (3) Partial deglycosylation by Endo D/H treatment
with exoglycosidases. Proximal GlcNAc remains on the modified Asn
with/without core Fuc. Black diamond Sia, black circle Gal, black
square GlcNAc, white circle Man, white triangle Fuc
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Target-Based Analysis MS is widely used to quantify
specific small molecules such as drugs, drug metabolites,
hormones, etc., with excellent precision and sensitivity (85,
86). In these methods, a sample is introduced from LC
through an ionizing spray, typically into a triple-quadrupole
MS. Within the MS, the first mass analyzer is set to pass the
target precursor molecular ion, rejecting components of
other mass-to-charge ratios (m/z). The target molecule is
then fragmented in a collision chamber by CID and passed
to a second mass analyzer set to pass a known specific
fragment. This two-stage selection affords great specificity
and thus improves the signal-to-noise ratio and allows the
quantification of target molecules by integrating the
precursor ion signals eluted by LC. An internal standard,
labeled with stable isotope, is often spiked into the sample
to provide a reference to which the target molecule is
compared. This technology, selected reaction monitoring
(SRM) applied for MS-based quantitative analysis of small
molecules, has been introduced to quantitative “shotgun”
proteomics to measure a particular peptide in a crude
sample with high selectivity and sensitivity (87–90). Thus,
the quantification of target peptide derived from particular
proteins, such as biomarker candidates, is performed by
spiking a defined amount of an appropriate internal
standard peptide (labeled with a stable isotope) into sample
mixtures. Multiple reaction monitoring (MRM), a modifi-
cation of SRM, measures the signal intensities of pre-listed
ions or peak areas of both precursor ions and their CID-
fragmented ions and thereby identifies and quantifies the
target peptide accurately and precisely by comparison with
reference peptide standards. MRM has been applied to
estimate the levels of five minor glycoproteins in human
serum (91), to measure the levels of biomarker candidates
in a mouse model of breast cancer (92), and to study the N-
linked glycosylation reaction in congenital disorders of
glycosylation type-I serum (93). Thus, MRM and SRM are
extremely powerful for biomarker discovery and candidate
validation (92). One of the obstacles to expanding the
MRM approach to large-scale studies is the need to
synthesize numerous reference peptides containing stable
isotopes; however, this problem has been partly resolved by
recent technological developments, such as QconCAT (94), in
which many isotopically labeled peptides can be synthesized
stoichiometrically as a concatenated precursor by expression
of genetically engineered DNA in cells cultured in media
containing stable isotope-labeled amino acids.
Conclusions
The MS-based glycoproteomics technologies described
here allow identification of thousands of glycoproteins in
plasma or crude cell extract and their sites of glycosylation
and enable detection of quantitative changes associated

























































Fig. 3 Identification and struc-
tural analysis of glycopeptides.
Glycopeptides eluted from LC is
introduced into MS through an
electrospray interface. CID of the
precursor ion produces fragment
ions dissociated preferentially at
glycosyl bond. The MS3 frag-
ments of peptide provide amino
acid sequence information
assigned by database search
tools, and the MS3 fragments of
glycan moeties provide structural
information on the glycan
attached on the glycopeptide.
Alternatively, ECD/ETD of the
glycopeptide precursor ion
cleaves preferentially at peptide
bonds and provides the amino
acid sequence and a glycosylated
amino acid with an additional
mass of attached glycans. Thus,
the detailed glycan structure can
be determined by concurrent
measurement with CID-MSn
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nologies contribute significantly to our understanding of
protein glycosylation; however, the discovery of serodiag-
nostic biomarkers is still challenging and requires further
improvements in speed, resolution, and in the dynamic
range of analysis. One promising approach to improve the
dynamic range and to detect trace plasma components is to
combine the glycopeptide capture methods described here
with other analytical techniques to concentrate a particular
subset of the proteome. For instance, Liu et al. (37)
combined immunoaffinity subtraction of abundant serum
proteins (c.f., albumin, immunoglobulin, transferrin, etc.,
which comprise ∼90% of the total protein mass) with
subsequent chemical fractionation based on cysteinyl
peptide and N-glycopeptide capture, and they identified
2,910 unique human plasma N-glycopeptides that corre-
spond to 662 N-glycoproteins and 1,553 N-glycosylated
sites and assigned numerous low-abundance plasma com-
ponents including 78 cytokines and cytokine receptors and
136 human cell differentiation molecules, e.g., interleukin-1,
macrophage colony-stimulation factor and tumor necrosis
factor receptor-1, which are present at the nanograms per
milliliter level in plasma (37). Thus, a proteome-wide
“discovery-based” proteomics approach is coupled with a
“target-based” approach, in which quantitative MS methods
such as MRM are used to evaluate limited sets of candidate
biomarkers in large sets of clinical samples. Finally, it
should be noted that technical advances in MS for
comprehensive structural analysis of glycans attached to
glycopeptides (95) is also critical for the discovery of new
biomarkers because the structure of glycan moiety is
extremely sensitive to the state of cell differentiation and
tumorigenesis.





Two N-glycopeptide samples are
labeled differentially with
PNGase in either H162 O(light: L)
or H162 O(heavy: H), combined,
and analyzed by LC/MS/MS.
The molecular mass of a
deglycosylated peptide increases
by 1Da (L) or 3Da (H) unit from
the calculated mass by the
PNGase mediated conversion of
N-glycosylated Asn to Asp. The
relative content of peptide in the
two N-glycopeptide samples is
estimated from the signal ratio
between the “light” and “heavy”
peptides, after correction of the
signal overlaps because of natu-
ral abundance of isotopes.
a Mass spectrum of a
deglycosylated peptide of hu-
man transferrin, residues 421–
433: CGLVPVLAENYNK,
treated in H182 O. b, c Mass
spectra of a mixture of peptides
treated with H162 O(L) and
H182 O(H) at a ratio of 1:3 and
1:1, respectively
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